Vanguard Group’s IGM Biosciences IGMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-767,154
Closed -$859K 4386
2025
Q2
$859K Sell
767,154
-108,415
-12% -$132K ﹤0.01% 3779
2025
Q1
$1.01M Sell
875,569
-20,781
-2% -$38.6K ﹤0.01% 3708
2024
Q4
$5.48M Buy
896,350
+6,150
+0.7% +$73.1K ﹤0.01% 3232
2024
Q3
$14.7M Buy
890,200
+11,579
+1% +$127K ﹤0.01% 2756
2024
Q2
$6.04M Buy
878,621
+24,963
+3% +$214K ﹤0.01% 3173
2024
Q1
$8.24M Sell
853,658
-43,491
-5% -$504K ﹤0.01% 3066
2023
Q4
$7.46M Sell
897,149
-2,858
-0.3% -$16.6K ﹤0.01% 3115
2023
Q3
$7.52M Buy
900,007
+202,719
+29% +$1.72M ﹤0.01% 3059
2023
Q2
$6.44M Buy
697,288
+116,926
+20% +$1.31M ﹤0.01% 3184
2023
Q1
$7.97M Buy
580,362
+3,195
+0.6% +$66.1K ﹤0.01% 3066
2022
Q4
$9.82M Buy
577,167
+57,190
+11% +$1.14M ﹤0.01% 2956
2022
Q3
$11.8M Buy
519,977
+9,044
+2% +$183K ﹤0.01% 2870
2022
Q2
$9.21M Sell
510,933
-319,144
-38% -$5.69M ﹤0.01% 3041
2022
Q1
$22.2M Buy
830,077
+415,028
+100% +$7.73M ﹤0.01% 2707
2021
Q4
$12.2M Buy
415,049
+2,490
+0.6% +$124K ﹤0.01% 3114
2021
Q3
$27.1M Buy
412,559
+2,756
+0.7% +$211K ﹤0.01% 2680
2021
Q2
$34.1M Buy
409,803
+5,702
+1% +$422K ﹤0.01% 2570
2021
Q1
$31M Sell
404,101
-36,830
-8% -$3.35M ﹤0.01% 2572
2020
Q4
$38.9M Buy
440,931
+69,077
+19% +$4.86M ﹤0.01% 2326
2020
Q3
$27.4M Sell
371,854
-100,018
-21% -$5.92M ﹤0.01% 2305
2020
Q2
$34.4M Sell
471,872
-28,007
-6% -$1.7M ﹤0.01% 2185
2020
Q1
$28.1M Sell
499,879
-4,802
-1% -$210K ﹤0.01% 2133
2019
Q4
$19.3M Buy
504,681
+479,681
+1,919% +$12.1M ﹤0.01% 2551
2019
Q3
$443K Buy
+25,000
New +$505K ﹤0.01% 3840

Other funds holding IGMS

Vanguard Group's IGMS Position: Q3 2025 in Review

Vanguard Group sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 767,154 shares — an estimated $859K sold.

Vanguard Group first reported a position in IGMS in Q3 2019 and held it in 24 quarters. The position peaked at $38.9M in Q4 2020. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.

  • Vanguard Group reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
  • Vanguard Group sold 767,154 IGM Biosciences shares in Q3 2025, an estimated $859K.
  • Vanguard Group first reported a position in IGM Biosciences in Q3 2019 and held it in 24 quarters.
  • Vanguard Group's IGM Biosciences position peaked at $38.9M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.